PS2 in breast cancer – alternative or complementary tool to steroid receptor status? Evaluation of 446 cases

Gion, Massimo; Mione, R; Pappagallo, Giovanni; Gatti, Carlo; Nascimben, O.; Bari, Md. Abdul; Leon, Antonette E.; Vinante, O.; Bruscagnin, G

doi:10.1038/bjc.1993.343

Cited by 29 publications

(15 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Rio et al (1987) have shown that PS2 expression is predominantly associated with ER positivity. The cytosolic content of PS2 in primary breast tumour biopsies has recently been shown to be a marker of favourable prognosis regarding response to adjuvant hormonal therapy (Predine et al, 1992), and time to relapse and death Predine et al, 1992;Gion et al, 1993). Similar results with respect to a relationship between PS2 expression and (relapse-free) survival were obtained when PS2 transcripts were analysed (Thompson et al, 1993).…”

supporting

confidence: 71%

“…However, no information is currently available in the literature regarding cytosolic PS2 levels and response to endocrine therapy for advanced disease. Irrespective of the technique used to assess PS2, as in the present study, the expression of PS2 in human primary breast tumours has shown to be correlated with that of ER or PgR Henry et al, 1989Henry et al, , 1991Skilton et al, 1989;Foekens et al, 1990Foekens et al, , 1993Schwartz et al, 1991;Cappelletti et al, 1992;Koerner et al, 1992;Predine et al, 1992;Thor et al, 1992;Gion et al, 1993;Luqmani et al, 1993b;Thompson et al, 1993).…”

Section: Discussionmentioning

confidence: 93%

“…Higher levels of PS2, measured by immunoassays in breast tumour cytosols, have shown to be associated with an increased length of relapse-free and overall survival in primary breast cancer Predine et al, 1992;Gion et al, 1993) and a more favourable response to adjuvant hormonal therapy (Predine et al, 1992). However, no information is currently available in the literature regarding cytosolic PS2 levels and response to endocrine therapy for advanced disease.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer

Foekens

Portengen²,

Look³

et al. 1994

Br J Cancer

View full text Add to dashboard Cite

PS2, an oestrogen-inducible protein, was measured in the cytosol of 230 primary tumours from patients who were subjected to first-line tamoxifen therapy for advanced disease without prior adjuvant therapy with tamoxifen. PS2 correlated positively with oestrogen receptor (ER, P < 0.01) and progesterone receptor content (PgR, P < 0.001), and with the length of progression-free survival (PFS, P = 0.05). Although not statistically significant, higher levels of PS2 (> or = 10 ng mg-1 protein) were also associated with increased probability of response to tamoxifen treatment and a longer total post-relapse survival (PRS). ER, PgR, menopausal status, site of disease and prior adjuvant chemotherapy were all associated with response to tamoxifen therapy and with PFS. In multivariate analysis for PFS, low levels of ER and PgR, visceral metastasis, a disease-free interval of less than 1 year and prior adjuvant chemotherapy were all significantly associated with an increased probability of a rapid disease progression after start of tamoxifen therapy. In the subset of 83 tumours with intermediate levels of ER and PgR (both > or = 10, but not both > or = 75 fmol mg-1 protein), PS2 was positively related with the length of PFS (P < 0.01) and PRS (P < 0.05). PS2 remained the strongest factor in multivariate analysis for PFS (P < 0.01) in this ER/PgR intermediate subgroup, but was not of predictive value in univariate or multivariate analysis for both PFS and PRS in tumours classified as ER/PgR low or high (> or = 75 fmol mg-1 protein). It is concluded that PS2 status may be used as a parameter, additional to ER and PgR, for better refinement of prediction of response to tamoxifen treatment in advanced breast cancer patients especially with intermediate ER/PgR levels in their primary tumour.

show abstract

supporting

confidence: 71%

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer

Foekens

Portengen²,

Look³

et al. 1994

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Let us point out, however, that the three mentioned above of four ER-negative, Cat D-positive patients died within 3 years of surgery, implying that Cat D immunodetection in hormone-independent [ER(-)] and thus anti-oestrogen-resistant cancers is an adverse prognostic indicator [5,22]. Cat D immunoreactivity was nonsignificantly associated with pS2 protein detection (Table 2), a finding in parallel with that of Gion et al [10].…”

Section: Discussionsupporting

confidence: 76%

Prognostic evaluation of oestrogen-regulated protein immunoreactivity in ductal invasive (NOS) breast cancer

Nakopoulou¹,

Lazaris²,

Baltas³

et al. 1995

Vichows Archiv A Pathol Anat

View full text Add to dashboard Cite

Determination of steroid receptors and several oestrogen-regulated proteins in mammary carcinomas is useful in the prediction of their evolution and of the likely success of endocrine therapy. Cathepsin D (Cat D), pS2 peptide and heat shock protein 27 (Hsp 27) were detected immunohistochemically in 63 infiltrating ductal (NOS) breast carcinomas, and our results were qualitatively correlated with several clinicopathological indicators and patients' overall survival. Cat D immunostaining of tumour cells was strongly associated with axillary nodal involvement (Pf = 0.0005) and so, it is directly connected with the metastatic capacity of malignant cells. pS2 immunoreactivity was correlated with oestrogen and progesterone receptor positivity (Pf = 0.0009 and Pf = 0.05 respectively) and, nonsignificantly, with good differentiation of the tumours (Pf = 0.06). Neoplastic cells expressing this protein are therefore characterised by a highly organised state of cellular physiology. Hsp 27 was expressed predominantly in tumours with one to four infiltrated lymph nodes (Pt = 0.05), and Hsp 27-positive patients were inclined to rather short survival, possibly due to chemotherapy resistance. In future, prognostic estimation of each one of the examined markers should be performed in specific large subgroups of patients. The findings of this study contribute to the establishment of criteria by which these subgroups should be formed.

show abstract

“…This protein is associated with ER and PR presence in breast tumors (13), it has been shown that pS2 is a predictor of response to tamoxifen treatment (24), and patients with pS2-positive breast tumors show greater relapse-free (13), progression-free, and overall survival rates (25,26). In patients with intermediate levels of ER and PR, pS2 has been able to predict tamoxifen effectiveness (27), allowing for therapy decisions to be made.…”

Section: Discussionmentioning

confidence: 97%

Development and evaluation of a competitive time-resolved immunofluorometric assay for the estrogen-regulated protein pS2

Zand

Jenkins

Diamandis

1999

J. Clin. Lab. Anal.

View full text Add to dashboard Cite

PS2 in breast cancer – alternative or complementary tool to steroid receptor status? Evaluation of 446 cases

Cited by 29 publications

References 26 publications

Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer

Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer

Prognostic evaluation of oestrogen-regulated protein immunoreactivity in ductal invasive (NOS) breast cancer

Development and evaluation of a competitive time-resolved immunofluorometric assay for the estrogen-regulated protein pS2

Contact Info

Product

Resources

About